Unlocking Pharmacy Value for Private Equity Firms

As pharmacy spending continues to climb – now representing up to 30% of healthcare costs and projected to grow even further – Private Equity (PE) firms are starting to take a closer look at pharmacy benefits as a critical lever for value creation in their Portfolio Companies.

Rising interest rates and lower company valuations have driven the need for PE firms to seek better operational efficiencies, with healthcare cost containment emerging as a key opportunity.

In this exclusive PE Hub Keynote Interview, Peter Lombardi, RxBenefits Executive Advisor for Private Equity, explores how PE firms are becoming more involved in healthcare cost oversight. He highlights how strategies like transparent contracts and independent clinical management can help contain costs while ensuring member health remains a priority.

Read the full interview to learn why interrogating pharmacy spend has become critical for PE firms aiming to tackle skyrocketing drug costs and protect member health.